vs

Side-by-side financial comparison of ARBOR REALTY TRUST INC (ABR) and Core Laboratories Inc. (CLB). Click either name above to swap in a different company.

ARBOR REALTY TRUST INC is the larger business by last-quarter revenue ($133.4M vs $121.8M, roughly 1.1× Core Laboratories Inc.). On growth, Core Laboratories Inc. posted the faster year-over-year revenue change (-1.4% vs -12.1%). Over the past eight quarters, Core Laboratories Inc.'s revenue compounded faster (-3.4% CAGR vs -8.9%).

Arbor Realty Trust Inc. is a U.S.-headquartered specialized real estate investment trust (REIT). It primarily provides structured financing solutions for multifamily residential and commercial real estate projects, including bridge loans, agency lending, and mezzanine financing. Its core market covers the U.S. real estate sector, serving property owners, developers and real estate investors nationwide.

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

ABR vs CLB — Head-to-Head

Bigger by revenue
ABR
ABR
1.1× larger
ABR
$133.4M
$121.8M
CLB
Growing faster (revenue YoY)
CLB
CLB
+10.6% gap
CLB
-1.4%
-12.1%
ABR
Faster 2-yr revenue CAGR
CLB
CLB
Annualised
CLB
-3.4%
-8.9%
ABR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ABR
ABR
CLB
CLB
Revenue
$133.4M
$121.8M
Net Profit
$5.1M
Gross Margin
Operating Margin
1.5%
Net Margin
4.2%
Revenue YoY
-12.1%
-1.4%
Net Profit YoY
EPS (diluted)
$0.08
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABR
ABR
CLB
CLB
Q1 26
$121.8M
Q4 25
$133.4M
$138.3M
Q3 25
$112.4M
$134.5M
Q2 25
$130.4M
$130.2M
Q1 25
$134.2M
$123.6M
Q4 24
$151.7M
$129.2M
Q3 24
$156.7M
$134.4M
Q2 24
$153.1M
$130.6M
Net Profit
ABR
ABR
CLB
CLB
Q1 26
$5.1M
Q4 25
$4.9M
Q3 25
$52.0M
$14.2M
Q2 25
$36.3M
$10.6M
Q1 25
$43.4M
$-154.0K
Q4 24
$7.4M
Q3 24
$73.5M
$11.7M
Q2 24
$61.8M
$9.0M
Gross Margin
ABR
ABR
CLB
CLB
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
ABR
ABR
CLB
CLB
Q1 26
1.5%
Q4 25
11.5%
Q3 25
15.6%
Q2 25
11.7%
Q1 25
3.6%
Q4 24
11.0%
Q3 24
14.7%
Q2 24
12.3%
Net Margin
ABR
ABR
CLB
CLB
Q1 26
4.2%
Q4 25
3.6%
Q3 25
46.3%
10.6%
Q2 25
27.8%
8.2%
Q1 25
32.3%
-0.1%
Q4 24
5.7%
Q3 24
46.9%
8.7%
Q2 24
40.4%
6.9%
EPS (diluted)
ABR
ABR
CLB
CLB
Q1 26
$0.11
Q4 25
$0.08
$0.11
Q3 25
$0.20
$0.30
Q2 25
$0.12
$0.22
Q1 25
$0.16
$0.00
Q4 24
$0.31
$0.15
Q3 24
$0.31
$0.25
Q2 24
$0.25
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABR
ABR
CLB
CLB
Cash + ST InvestmentsLiquidity on hand
$482.9M
$22.8M
Total DebtLower is stronger
$11.1B
Stockholders' EquityBook value
$3.0B
$275.1M
Total Assets
$14.5B
$587.7M
Debt / EquityLower = less leverage
3.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABR
ABR
CLB
CLB
Q1 26
$22.8M
Q4 25
$482.9M
$22.7M
Q3 25
$423.4M
$25.6M
Q2 25
$255.7M
$31.2M
Q1 25
$308.8M
$22.1M
Q4 24
$503.8M
$19.2M
Q3 24
$687.5M
$21.5M
Q2 24
$737.5M
$17.7M
Total Debt
ABR
ABR
CLB
CLB
Q1 26
Q4 25
$11.1B
$110.3M
Q3 25
$10.4B
$114.1M
Q2 25
$10.1B
$124.6M
Q1 25
$9.9B
$124.4M
Q4 24
$10.0B
$126.1M
Q3 24
$10.3B
$139.9M
Q2 24
$10.6B
$147.6M
Stockholders' Equity
ABR
ABR
CLB
CLB
Q1 26
$275.1M
Q4 25
$3.0B
$266.0M
Q3 25
$3.0B
$271.3M
Q2 25
$3.0B
$261.3M
Q1 25
$3.0B
$253.4M
Q4 24
$3.0B
$246.6M
Q3 24
$3.0B
$250.7M
Q2 24
$3.1B
$240.3M
Total Assets
ABR
ABR
CLB
CLB
Q1 26
$587.7M
Q4 25
$14.5B
$584.0M
Q3 25
$13.9B
$591.4M
Q2 25
$13.6B
$602.1M
Q1 25
$13.4B
$591.5M
Q4 24
$13.5B
$585.1M
Q3 24
$13.9B
$600.5M
Q2 24
$14.2B
$597.8M
Debt / Equity
ABR
ABR
CLB
CLB
Q1 26
Q4 25
3.75×
0.41×
Q3 25
3.47×
0.42×
Q2 25
3.40×
0.48×
Q1 25
3.29×
0.49×
Q4 24
3.29×
0.51×
Q3 24
3.40×
0.56×
Q2 24
3.47×
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABR
ABR
CLB
CLB
Operating Cash FlowLast quarter
$372.4M
$4.0M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABR
ABR
CLB
CLB
Q1 26
$4.0M
Q4 25
$372.4M
$7.9M
Q3 25
$178.7M
$8.5M
Q2 25
$60.0M
$13.9M
Q1 25
$150.5M
$6.7M
Q4 24
$461.5M
$20.6M
Q3 24
$85.0M
$13.1M
Q2 24
$69.9M
$17.1M
Free Cash Flow
ABR
ABR
CLB
CLB
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
Q2 25
$10.4M
Q1 25
$3.9M
Q4 24
$17.4M
Q3 24
$10.4M
Q2 24
$14.3M
FCF Margin
ABR
ABR
CLB
CLB
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
Q2 25
8.0%
Q1 25
3.1%
Q4 24
13.4%
Q3 24
7.7%
Q2 24
10.9%
Capex Intensity
ABR
ABR
CLB
CLB
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
2.7%
Q1 25
2.3%
Q4 24
2.5%
Q3 24
2.0%
Q2 24
2.2%
Cash Conversion
ABR
ABR
CLB
CLB
Q1 26
0.77×
Q4 25
1.61×
Q3 25
3.44×
0.60×
Q2 25
1.65×
1.31×
Q1 25
3.47×
Q4 24
2.78×
Q3 24
1.16×
1.12×
Q2 24
1.13×
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons